Order results by:
| Issue | Title | |
| Vol 10, No 2 (2014) | RIVAROXABAN IN PATIENTS STABILIZED AFTER A ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION. RESULTS FROM THE ATLAS ACS-2–TIMI-51 TRIAL | Abstract similar documents |
| J. L. Mega, E. Braunwald, S. A. Murphy, A. N. Plotnikov, P. Burton, R. G. Kiss, A. Parkhomenko, M. Tendera, P. Widimsky, C. M. Gibson | ||
| "... лечением (m-ITT). Результаты. У больных ИМ с подъемом сегмента ST ривароксабан снизил в сравнении с ..." | ||
| Vol 14, No 5 (2018) | Bayer registered a new indication for rivaroxaban for use in patients with coronary heart disease or peripheral artery disease in the European Union and USA | Abstract similar documents |
| Bayer Company Press Release | ||
| "... антикоагулянта ривароксабана в дозе 2,5 мг 2 р/д в сочетании с 75-100 мг ацетилсалициловой кислоты один раз в ..." | ||
| Vol 19, No 5 (2023) | Pharmacogenetics and pharmacokinetics of rivaroxaban in patients with atrial fibrillation and chronic kidney disease | Abstract similar documents |
| N. A. Shatalova, D. A. Sychev, K. B. Mirzaev, A. I. Kochetkov, E. Yu. Ebzeeva, V. B. Dashabylova, P. O. Bochkov, S. N. Tuchkova, S. V. Glagolev | ||
| "... and CT genotypes of the rs35599367 polymorphism of the CYP3A4 gene, and carriers of the CC and AC ..." | ||
| Vol 13, No 4 (2017) | PROLONGED DUAL ANTIPLATELET THERAPY AFTER MYOCARDIAL INFARCTION: WHAT THE RESULTS OF THE PEGASUS-TIMI 54 TRIAL SHOW | Abstract similar documents |
| I. S. Yavelov | ||
| "... . The results of a large randomized placebo-controlled PEGASUS-TIMI 54 trial on the evaluation of efficacy ..." | ||
| Vol 9, No 2 (2013) | ELECTROCARDIOGRAM ST SEGMENT DEPRESSION AND ELEVATION IN STRESS-TESTING | Abstract similar documents |
| D. A. Kuzhel, G. V. Matyushin, T. D. Fedorova, N. V. Kovaleva, E. A. Savchenko, S. E. Golovenkin | ||
| "... . Отведения с подъемом сегмента ST указывают на пораженную коронарную артерию. ..." | ||
| Vol 12, No 5 (2016) | The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin | Abstract similar documents |
| I. Yu. Koroleva, I. V. Kolesnichenko, V. P. Nosov, M. V. Zlobin, D. I. Abelevich | ||
| "... Цель. Изучить влияние терапии ривароксабаном на частоту развития кардиоэмболических инсультов и ..." | ||
| Vol 10, No 3 (2014) | PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD | Abstract similar documents |
| L. Y. Koroleva, I. V. Kolesnichenko, V. P. Nosov, I. I. Gritsenko, E. S. Timoschenko | ||
| "... , имеющим самый большой перечень показаний к применению и очень привлекательным, является ривароксабан. ..." | ||
| Vol 11, No 6 (2015) | PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD | Abstract similar documents |
| L. Y. Koroleva, I. V. Kolesnichenko, V. P. Nosov, I. I. Gritsenko, E. S. Timoschenko | ||
| "... , имеющим самый большой перечень показаний к применению и очень привлекательным, является ривароксабан. ..." | ||
| Vol 10, No 5 (2014) | EVOLUTION OF THROMBOLYTIC THERAPY IN THE TREATMENT OF MYOCARDIAL INFARCTION | Abstract similar documents |
| P. G. Kesov, O. M. Reytblat, Z. M. Safiullina, S. V. Shalaev | ||
| Vol 8, No 3 (2012) | RIVAROXABAN IN THE PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ATRIAL FIBRILLATION | Abstract similar documents |
| M. Yu. Gilyarov | ||
| "... средства, в частности, ривароксабан. Эффективность и безопасность ривароксабана рассматривается на основе ..." | ||
| Vol 8, No 4 (2012) | THE RISK OF BLEEDINGS IN PATIENTS WITH ATRIAL FIBRILLATION DURING ANTICOAGULANT THERAPY | Abstract similar documents |
| M. Yu. Gilyarov | ||
| "... безопасности отдельно рассматривается ривароксабан. ..." | ||
| Vol 17, No 2 (2021) | The Role of Rivaroxaban in a Comprehensive Protection Strategy for Patients with Atrial Fibrillation | Abstract similar documents |
| I. A. Zolotovskaya, V. D. Sabanova, I. L. Davydkin | ||
| "... сердечно-сосудистых заболеваний. На сегодняшний день ривароксабан имеет целый ряд убедительных и надежных ..." | ||
| Vol 15, No 5 (2019) | Rivaroxaban-Associated Hepatotoxicity: a Clinical Case and Literature Review | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov | ||
| "... антикоагулянты, в частности, ривароксабан (ингибитор Xa фактора), широко используются при различных показаниях ..." | ||
| Vol 20, No 1 (2024) | Clinical factors associated with the no/slow-reflow phenomenon in patients with acute coronary syndrome | Abstract similar documents |
| E. V. Konstantinova, Yu. S. Ilin, A. A. Velikotskiy, N. A. Rakhimi, A. A. Bogdanova, A. V. Ploshchenkov | ||
| "... syndrome (ACS) undergoing primary percutaneous coronary intervention (PCI), and to study factors associated ..." | ||
| Vol 18, No 5 (2022) | Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature Review | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova | ||
| "... блокаторы тромбина (дабигатран), либо блокаторы IIа фактора (апиксабан, ривароксабан, эдоксабан). Согласно ..." | ||
| Vol 12, No 4 (2016) | Application of rivaroxaban in clinical practice: results of a prospective observational study XANTUS in patients with atrial fibrillation | Abstract similar documents |
| S. G. Kanorskii | ||
| "... В исследовании XANTUS оценены безопасность и эффективность ингибитора фактора Xa ривароксабана в ..." | ||
| Vol 13, No 1 (2017) | CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION | Abstract similar documents |
| S. V. Nedogoda, I. N. Barykina, A. S. Salasiuk, V. O. Smirnova | ||
| "... Цель. Сравнить экономическую эффективность применения прямых ингибиторов Ха фактора ривароксабана ..." | ||
| Vol 13, No 5 (2017) | DRUG INTERACTIONS OF NEW ORAL ANTICOAGULANTS: INSIDE AND OUTSIDE TABLE CELLS | Abstract similar documents |
| S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov | ||
| "... В некоторых отечественных публикациях высказывается мнение о том, что ривароксабан обладает ..." | ||
| Vol 16, No 2 (2020) | The Risk of Myocardial Infarction in Patients with Atrial Fibrillation Taking a Direct Thrombin Inhibitor: Myths and Reality | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov | ||
| Vol 14, No 4 (2018) | Possibilities of Using Rivaroxaban in Elderly Patients with Atrial Fibrillation: Data from Randomized Studies and Real Clinical Practice | Abstract similar documents |
| N. M. Vorobyeva, O. N. kacheva | ||
| "... В обзорной статье рассматриваются возможности применения ривароксабана у пожилых пациентов с ..." | ||
| Vol 15, No 2 (2019) | Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology | Abstract similar documents |
| S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov, G. Yu. Trufanova | ||
| "... синдромом старческой астении или «хрупкости» (frailty), приведены два положения, выделяющие ривароксабан ..." | ||
| Vol 15, No 4 (2019) | Elderly Patients with Atrial Fibrillation: Focus on Comorbidity and Safety of Anticoagulant Therapy | Abstract similar documents |
| D. A. Napalkov, A. A. Sokolova | ||
| "... благоприятный профиль эффективности и безопасности ривароксабана в сравнении с варфарином у пациентов 75 лет и ..." | ||
| Vol 15, No 2 (2019) | Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology | Abstract similar documents |
| Sergey N. Bel'diev, Irina V. Medvedeva, Dmitry Yu. Platonov, Galina Yu. Trufanova | ||
| "... » (frailty), приведены два положения, выделяющие ривароксабан среди других прямых пероральных антикоагулянтов ..." | ||
| Vol 13, No 5 (2017) | Drug interactions of non-vitamin K antagonist oral anticoagulants: inside and outside table cells | Abstract similar documents |
| Sergey Nikolaevich Bel'diev, Irina Vladimirovna Medvedeva, Dmitry Jur'evich Platonov | ||
| "... В некоторых отечественных публикациях высказывается мнение о том, что ривароксабан обладает ..." | ||
| Vol 5, No 5 (2009) | MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION IN PATIENTS PRESENTING WITH PERSISTENT ST-SEGMENT ELEVATION | Abstract similar documents |
| Frans Van de Werf, Jeroen Bax, Amadeo Betriu, Carina Blomstrom-Lundqvist, Filippo Crea, Volkmar Falk, Gerasimos Filippatos, Keith Fox, Kurt Huber, Adnan Kastrati, Annika Rosengren, P. Gabriel Steg, Marco Tubaro, Freek Verheugt, Franz Weidinger, Michael Weis, M. O. Evseev | ||
| Vol 5, No 6 (2009) | MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION IN PATIENTS PRESENTING WITH PERSISTENT ST-SEGMENT ELEVATION (ENDING) | Abstract similar documents |
| Frans Van de Werf, Jeroen Bax, Amadeo Betriu, Carina Blomstrom-Lundqvist, Filippo Crea, Volkmar Falk, Gerasimos Filippatos, Keith Fox, Kurt Huber, Adnan Kastrati, Annika Rosengren, P. Gabriel Steg, Marco Tubaro, Freek Verheugt, Franz Weidinger, Michael Weis, M. O. Evseev | ||
| Vol 12, No 1 (2016) | Interaction of rivaroxaban with amiodarone, verapamil and diltiazem in patients with atrial fibrillation: terra incognita | Abstract similar documents |
| S. N. Bel'diev | ||
| "... В настоящее время отсутствуют общепринятые рекомендации по применению ривароксабана совместно с ..." | ||
| Vol 12, No 3 (2016) | THE ADVANCED TACTICS OF THE MANAGEMENT OF PATIENTS WITH VENOUS THROMBOEMBOLISM: THE ROLE OF RIVAROXABAN AT VARIOUS STAGES OF TREATMENT | Abstract PDF (Eng) similar documents |
| S. R. Gilyarevskiy | ||
| "... монотерапии ривароксабаном. ..." | ||
| Vol 14, No 6 (2018) | The Results of Rivaroxaban Studies COMMANDER HF and MARINER Were Published. Bayer Company Press Release . | Abstract PDF (Eng) similar documents |
| artilce Editorial | ||
| Vol 12, No 1 (2016) | Взаимодействие ривароксабана с амиодароном, верапамилом и дилтиаземом у пациентов с фибрилляцией предсердий: terra incognita | Abstract similar documents |
| "... В настоящее время отсутствуют общепринятые рекомендации по применению ривароксабана совместно с ..." | ||
| Vol 18, No 3 (2022) | Clinically Significant Drug Interactions for Direct Oral Anticoagulants: State of the Art | Abstract similar documents |
| S. R. Gilyarevsky | ||
| "... практике. Приводятся данные о лекарственных взаимодействиях апиксабана, ривароксабана и дабигатрана с ..." | ||
| Vol 18, No 6 (2022) | Effect of ABCB1 Gene Carriage and Drug-Drug Interactions on Apixaban and Rivaroxaban Pharmacokinetics and Clinical Outcomes in Patients with Atrial Fibrillation and Deep Vein Thrombosis | Abstract similar documents |
| L. V. Fedina, I. N. Sychev, T. D. Rastvorova, E. V. Strigunkova, A. A. Kachanova, Z. A. Sozaeva, P. O. Bochkov, A. V. Vardanyan, K. B. Mirzayev, D. A. Sychev | ||
| "... включено 92 пациента (50 пациентов получали апиксабан и 42 – ривароксабан) с неклапанной фибрилляцией ..." | ||
| Vol 19, No 1 (2023) | Value of Safety of Anticoagulant Therapy in Elderly Patient with Atrial Fibrillation and High Risk of Bleeding | Abstract similar documents |
| N. M. Vorobyeva, O. N. Tkacheva | ||
| "... , демонстрирующая высокую безопасность ривароксабана у больных старше 80 лет, с высоким риском кровотечений и ..." | ||
| Vol 12, No 2 (2016) | THE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN CLINICAL PRACTICE | Abstract similar documents |
| S. V. Moiseev | ||
| "... Новые пероральные антикоагулянты, ингибирующие фактор Xa (ривароксабан, апиксабан, эдоксабан) или ..." | ||
| Vol 12, No 4 (2016) | Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true | Abstract similar documents |
| Yu. A. Bunin, S. V. Miklishanskaya | ||
| Vol 13, No 1 (2017) | DATA OF CLINICAL PRACTICE AS A TOOL FOR CHOICE OF DIRECT ORAL ANTICOAGULANT | Abstract similar documents |
| D. А. Napalkov, A. A. Sokolova, V. V. Fomin | ||
| "... ARISTOTLE. Ривароксабан, напротив, продемонстрировал наихудший профиль безопасности, чаще всего вызывая ..." | ||
| Vol 13, No 3 (2017) | PHARMACOGENETIC ASPECTS OF NEW ORAL ANTICOAGULANTS APPLICATION | Abstract similar documents |
| A. V. Kryukov, D. A. Sychev, O. V. Tereshchenko | ||
| "... кровотечения при приеме ривароксабана у пациента-носителя аллельных вариантов по полиморфизмам rs2032582 и rs ..." | ||
| Vol 7, No 5 (2011) | ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: RECENT APPROACHES AND NEAR PERSPECTIVES | Abstract similar documents |
| Ya. P. Dovgalevskiy, L. E. Kuvshinova, I. V. Graifer, N. V. Furman, P. Ya. Dovgalevskiy | ||
| Vol 9, No 3 (2013) | ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT | Abstract similar documents |
| E. L. Dolgova, I. M. Sokolov, Yu. G. Shvarts | ||
| Vol 11, No 3 (2015) | ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION | Abstract similar documents |
| A. V. Rudakova | ||
| "... , дабигатрана и ривароксабана). Цель. Анализ влияния на бюджет применения апиксабана в качестве альтернативы ..." | ||
| Vol 9, No 4 (2013) | COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS | Abstract similar documents |
| V. A. Sulimov, D. A. Napalkov, A. A. Sokolova | ||
| Vol 10, No 4 (2014) | NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY | Abstract similar documents |
| D. A. Napalkov, A. A. Sokolova | ||
| "... нового поколения, включающих дабигатран, ривароксабан и апиксабан, с позиции безопасности терапии ..." | ||
| Vol 16, No 1 (2020) | Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice | Abstract similar documents |
| A. A. Zarudsky, A. A. Gavrilova, Т. S. Filinichenko | ||
| Vol 16, No 2 (2020) | Specificities of Approaches to Anticoagulant Therapy in Comorbid Patients with Atrial Fibrillation, Diabetes Mellitus and Impaired Kidney Function | Abstract similar documents |
| N. V. Drobotya, E. Sh. Guseynova, A. A. Pirozhenko | ||
| "... прогрессирование ухудшения фильтрационной функции почек. Этим требованиям может соответствовать ривароксабан, при ..." | ||
| Vol 16, No 3 (2020) | Coronary Artery Disease with a High Risk of Complications: How to Identify Such Patients and Choose Management Tactics? | Abstract similar documents |
| S. G. Kanorskii | ||
| "... атеросклеротических сердечно-сосудистых заболеваний. При использовании низких доз ривароксабана и аспирина в группах ..." | ||
| Vol 16, No 4 (2020) | Cardiovascular Comorbidity: Patient with Coronary Artery Disease and Peripheral Artery Atherosclerosis. How to Identify and Manage the Risks of Ischemic Events? | Abstract similar documents |
| O. L. Barbarash, V. V. Kashtalap, I. A. Shibanova | ||
| "... атеросклероза периферических артерий с помощью комбинации антикоагулянта – ривароксабана и антиагреганта ..." | ||
| Vol 14, No 5 (2018) | Anticoagulant Therapy in Difficult Patients with Atrial Fibrillation: When the Risks of Embolism and Bleeding Are Comparable | Abstract similar documents |
| D. A. Napalkov, A. A. Sokolova, M. A. Gabitova, L. N. Uddin | ||
| "... ривароксабана. Была продемонстрирована хорошая эффективность и безопасность препарата как в сниженной, так и в ..." | ||
| Vol 16, No 5 (2020) | New Pharmacogenetic Markers to Predict the Risk of Bleeding During Taking of Direct Oral Anticoagulants | Abstract PDF (Eng) similar documents |
| K. B. Mirzaev, D. V. Ivashchenko, I. V. Volodin, E. A. Grishina, K. A. Akmalova, A. A. Kachanova, A. I. Skripka, R. M. Minnigulov, T. E. Morozova, O. A. Baturina, A. N. Levanov, T. V. Shelekhova, A. I. Kalinkin, D. A. Napalkov, A. A. Sokolova, D. A. Andreev, I. N. Sychev, P. O. Bochkov, D. A. Sychev | ||
| "... применения ривароксабана и дабигатрана у пациентов различных нозологических групп: фибрилляция предсердий ..." | ||
| Vol 17, No 1 (2021) | Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction | Abstract similar documents |
| Z. D. Kobalava, A. A. Shavarov, M. V. Vatsik-Gorodetskaya | ||
| Vol 17, No 2 (2021) | Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation in Real Clinical Practice: in Appropriate Dose Reductions | Abstract similar documents |
| V. A. Ionin, O. I. Bliznuk, E. I. Baranova, E. V. Shlyakhto | ||
| "... 57,7% (384/665) больных ФП: ривароксабан - 180 (46,9%), дабигатран - 110 (28,6%) больных, апиксабан ..." | ||
| Vol 17, No 2 (2021) | Analysis of Anticoagulant Therapy in the Elderly Patients, in Clinical Practice of Family Medicine Centers in the Kyrgyz Republic | Abstract similar documents |
| S. M. Mamatov, B. Kanat kyzy, A. O. Musakeev, N. K. Kinderbaeva, T. J. Tagaev | ||
| "... больным был назначен варфарин, адекватная антикоагуляция к концу года составила всего 11,8%. Ривароксабан ..." | ||
| Vol 17, No 3 (2021) | An Integrated Approach to the Management of a Multimorbid Patient with Atrial Fibrillation from the Standpoint of Modern Guidelines: Rivaroxaban is in Focus | Abstract similar documents |
| V. N. Larina, O. Sh. Oynotkinova, A. P. Majorova, G. A. Egiazarian, T. Yu. Demidova | ||
| "... антикоагулянтную защиту пациентов с ФП, авторами статьи рассматривается ривароксабан. Профиль эффективности ..." | ||
| Vol 13, No 2 (2017) | RIVAROXABAN HAS DEMONSTRATED AN ADVANTAGE OVER ACETYLSALICYLIC ACID IN PREVENTING THE RECURRENCE OF VENOUS THROMBOEMBOLIC EVENTS IN THE EINSTEIN CHOICE STUDY | Abstract similar documents |
| . Editorial | ||
| "... эффективность и безопасность ривароксабана в дозах 20 мг 1 р/д*, 10 мг 1 р/д и ацетилсалициловой кислоты в дозе ..." | ||
| Vol 16, No 1 (2020) | Clinical Significance of Thrombin Blockade with Low Doses (2.5 mg) of Rivaroxaban in Ischemic Heart Disease Patients | Abstract similar documents |
| A. B. Sumarokov, L. I. Buryachkovskaya, Y. V. Docenko, M. S. Kurochkin, N. V. Lomakin | ||
| "... клинического применения оказалась комбинация ривароксабана в дозе 2,5 мг 2 раза в день и антиагрегантной ..." | ||
| Vol 11, No 5 (2015) | New data of the real clinical practice confirms low incidence of major bleeding when using rivaroxaban in patients with non-valvular atrial fibrillation | Abstract similar documents |
| article Editorial | ||
| "... предсердий, подтверждают низкую частоту кровотечений при использовании ривароксабана (Ксарелто®) • Недавно ..." | ||
| Vol 17, No 6 (2021) | Renal Function Protection as an Important Component of a Comprehensive Approach to the Management of Patients with Atrial Fibrillation | Abstract similar documents |
| T. V. Pavlova | ||
| "... kidney disease (CKD) are two diseases that can coexist in a patient. The risk of ac thromboembolic ..." | ||
| Vol 17, No 4 (2021) | Effect of Direct Oral Anticoagulants for Ulcer Epithelization and Laser Doppler Flowmetry Parameters In Patients with Diabetic Foot Syndrome and Atrial Fibrillation | Abstract similar documents |
| V. I. Petrov, N. V. Rogova, T. N. Кuzmina, A. S. Lishuta | ||
| "... и ривароксабан (группа 1; n=24), или комплексная терапия СДС и дабигатран (группа 2; n=22 ..." | ||
| Vol 13, No 5 (2017) | ADHERENCE TO THE USE OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION – THE WAY TO SOLVE THE PROBLEM OF EFFICACY AND SAFETY OF TREATMENT | Abstract similar documents |
| S. G. Kanorskii | ||
| "... , вероятно, будут зависеть от приверженности к лечению. Ривароксабан можно назначать в фиксированных дозах ..." | ||
| Vol 13, No 6 (2017) | PREDICTORS OF THE RISK OF HEMORRHAGIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION RECEIVING LONGTERM THERAPY WITH DIRECT ORAL ANTICOAGULANTS | Abstract similar documents |
| A. А. Sokolova, A. V. Zhilenko, I. L. Tsarev,, D. A. Napalkov, V. V. Fomin | ||
| "... – ривароксабан и апиксабан), были включены в когортное исследование в параллельных группах. Помимо оценки ..." | ||
| Vol 11, No 1 (2015) | PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION | Abstract similar documents |
| A. V. Rudakova | ||
| "... препаратами (ацетилсалициловая кислота) и новыми пероральными антикоагулянтами (апиксабан, ривароксабан и ..." | ||
| Vol 15, No 6 (2019) | Safety of Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation | Abstract similar documents |
| M. A. Gabitova, P. M. Krupenin, A. A. Sokolova, D. A. Napalkov, V. V. Fomin | ||
| "... пациенты ≥75 лет с подтвержденной ФП, получающие дабигатран в сниженной дозе, апиксабан или ривароксабан в ..." | ||
| Vol 15, No 6 (2019) | New Opportunities for Improving the Prognosis of Patients with Chronic Ischemic Heart Disease | Abstract similar documents |
| N. B. Perepech | ||
| "... с хронической ИБС или заболеванием периферических артерий комбинированной терапии ривароксабаном и ..." | ||
| Vol 16, No 1 (2020) | The Efficacy, Safety and Adherence to Treatment when New Anticoagulants Taking in Over 75 Years Old Patients with Atrial Fibrillation | Abstract similar documents |
| A. N. Turov, S. V. Panfilov, О. V. Tschiglinzeva | ||
| "... ,9±4,9) мес дабигатран принимали 38,5% (n=166), ривароксабан – 41,3% (n=178), апиксабан – 20,2% (n=87 ..." | ||
| Vol 16, No 2 (2020) | Off-Label Medicines Use: Complex Problem of Modern Clinical Practice | Abstract similar documents |
| S. R. Gilyarevskiy | ||
| Vol 14, No 4 (2018) | Hepatotoxicity of New Oral Anticoagulants | Abstract similar documents |
| A. R. Kasimova, A. V. Philippova (Guryanova), A. S. Kolbin | ||
| Vol 16, No 6 (2020) | An Elderly Comorbid Patient with Atrial Fibrillation: What is Important to Know and What Should be Considered When Prescribing Anticoagulants? | Abstract similar documents |
| T. V. Pavlova | ||
| "... антикоагулянт прямого действия ривароксабан по результатам РКИ ROCKET AF в подгруппе больных в возрасте 75 лет и ..." | ||
| Vol 15, No 3 (2019) | Treatment of Patients with Stable Manifestations of Atherosclerosis: New Opportunities | Abstract similar documents |
| article Editorial | ||
| "... как коагуляционного, так и тромбоцитарного звена). Эксперты отметили, что терапия ривароксабаном 2 ..." | ||
| Vol 19, No 3 (2023) | Current insights into the possible role of laboratory monitoring of effectiveness and safety of direct oral anticoagulants | Abstract similar documents |
| S. R. Gilyarevsky, N. K. Vereina, M. V. Golshmid | ||
| Vol 20, No 4 (2024) | Should a physician use the Beers criteria when prescribing direct oral anticoagulants to elderly patients? | Abstract similar documents |
| N. M. Vorobyeva, I. P. Malaya, V. D. Zakiev, O. N. Tkacheva | ||
| "... от 2023 г. изменилось мнение экспертов в отношении ривароксабана — вместо "использовать с ..." | ||
| Vol 13, No 5 (2017) | RIVAROXABAN OF THE BAYER COMPANY SIGNIFICANTLY (BY 24%) REDUCES THE RISK OF STROKE, CARDIOVASCULAR DEATH AND MYOCARDIAL INFARCTION IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE OR PERIPHERAL ARTERIAL DISEASE | Abstract similar documents |
| статья Редакционная | ||
| Vol 18, No 6 (2022) | Left Ventricular Thrombosis: Current Perspective and Use of Direct Oral Anticoagulants | Abstract similar documents |
| A. D. Aga, A. A. Sokolova, D. A. Napalkov | ||
| Vol 12, No 5 (2016) | Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease | Abstract similar documents |
| I. S. Daabul, A. A. Sokolova, D. A. Napalkov | ||
| Vol 15, No 5 (2019) | Anticoagulant Therapy as a Tool for the Prevention of Cognitive Impairment Associated with Atrial Fibrillation | Abstract similar documents |
| O. D. Ostroumova, A. I. Kochetkov, S. P. Korchagina, T. M. Ostroumova, M. S. Chernyaeva, A. A. Kirichenko | ||
| "... заслуживает ривароксабан как препарат, отличающейся благоприятным профилем эффективности в отношении первичной ..." | ||
| Vol 18, No 1 (2022) | The Impact of Combination Therapy with Rivaroxaban and Acetylsalicylic Acid in Patients with Coronary Heart Disease on the Achievement of the Target for Reducing Mortality from Cardiovascular Diseases of the Federal Project "Fight against Cardiovascular Diseases" | Abstract similar documents |
| M. V. Zhuravleva, A. V. Panov, A. R. Kuksenok | ||
| "... Цель. Оценить влияние применения комбинированной терапии ривароксабаном и ацетилсалициловой ..." | ||
| Vol 12, No 6 (2016) | NEW DATA OF EXTENSIVE RESEARCH PROGRAM AND THE RESULTS OF STUDIES IN REAL CLINICAL PRACTICE FROM DIFFERENT COUNTRIES REAFFIRMED THE HIGH EFFICACY AND A FAVORABLE SAFETY PROFILE OF RIVAROXABAN (XARELTO®) FROM THE BAYER COMPANY PRESS RELEASE OF THE BAYER COMPANY | Abstract similar documents |
| article editorial | ||
| Vol 17, No 6 (2021) | Anticoagulants after Discharge in Patients with COVID-19: What we Know at the End of 2021 | Abstract similar documents |
| I. S. Yavelov | ||
| "... эффективности и безопасности применения прямого перорального антикоагулянта ривароксабана в дозе 10 мг 1 ..." | ||
| Vol 4, No 2 (2008) | ANTICOAGULANTS IN THERAPY OF PATIENTS WITH ACUTE CORONARY SYNDROME WITHOUT ST SEGMENT ELEVATION: WHICH DRUG TO BE CHOSEN? | Abstract similar documents |
| A. L. Komarov, E. P. Panchenko | ||
| "... Problem of anticoagulant choice in patients with acute coronary syndrome (ACS) is discussed ..." | ||
| Vol 12, No 4 (2016) | Adherence to attendance at outpatient clinic, quality of prehospital therapy, and direct outcome of acute coronary syndrome: analysis within LIS-3 registry | Abstract similar documents |
| Yu. V. Semenova, N. P. Kutishenko, A. V. Zagebelnyy, A. D. Deev, M. L. Ginzburg, S. Yu. Martsevich | ||
| "... ) on direct outcome of acute coronary syndrome (ACS). Material and methods. Patients (n=320) hospitalized ..." | ||
| Vol 19, No 6 (2023) | New possibilities for lipid level control using inclisiran — prospects for interaction between a cardiologist and a neurologist | Abstract similar documents |
| A. B. Skiba, M. V. Menzorov, V. D. Puchek, I. M. Buchin, I. I. Polyakov, E. N. Menzorova | ||
| Vol 14, No 4 (2018) | Physician’s Adherence to Clinical Guidelines for in-Hospital Anticoagulant Prescribing | Abstract similar documents |
| A. A. Chernov, E. V. Kleymenova, D. A. Sychev, L. P. Yashina, M. D. Nigmatkulova, V. A. Otdelenov, S. A. Payushchik | ||
| "... Background. Anticoagulants (AC) are the high-risk drugs. Their safety closely depends on physician ..." | ||
| Vol 19, No 3 (2023) | Recurrent bleeding during standard anticoagulant therapy in comorbid patients with atrial fibrillation: a clinical case report | Abstract similar documents |
| A. A. Kudriavtseva, E. V. Kolpachkova, Z. A. Gebekova, T. A. Sadulaeva, A. A. Sokolova, D. A. Napalkov | ||
| "... ривароксабана у пациентки 72 лет с ФП без нарушений функции почек и печени. В связи с повышением остаточной ..." | ||
| Vol 16, No 6 (2020) | Actual Issues of Ischemic and Hemorrhagic Events Risk Management During Antithrombotic Therapy in Patients with Acute Coronary Syndrome | Abstract similar documents |
| R. M. Velieva, T. B. Pecherina, A. S. Vorobiev, V. V. Kashtalap, D. Yu. Sedykh | ||
| "... ) in patients with acute coronary syndrome (ACS) remains the subject of scientific and practical discussion ..." | ||
| Vol 12, No 2 (2016) | THE RESULTS OF USE OF NEW NATIVE THROMBOLYTIC IN CLINICAL PRACTICE | Abstract similar documents |
| E. S. Mazur, R. M. Rabinovich, V. V. Mazur, N. S. Kuznetsova, E. A. Kudryashova, S. V. Veselov | ||
| "... % in 180 min was reached in 66% of patients and angiographic effect TIMI 2-3 – in 60% of patients ..." | ||
| Vol 2, No 4 (2006) | THROMBOLYTIC THERAPY IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION | Abstract similar documents |
| E. V. Konstantinova, A. V. Magnitskyi, N. A. Schostak | ||
| "... infarction are analyzed: GISSI, ISSIS, TIMI, GUSTO, INJECT, ASSENT. The possibility to increase in efficacy ..." | ||
| Vol 5, No 2 (2009) | THE STRUCTURE OF DRUG PRESCRIPTION IN ACUTE CORONARY SYNDROME WITHOUT ST SEGMENT ELEVATION ON THE FIRST DAY OF HOSPITAL THERAPY | Abstract PDF (Eng) similar documents |
| O. V. Reshetko, N. V. Furman, R. M. Magdeev | ||
| "... coronary syndrome (ACS) without elevation ST during first 24 hours. Results. Prescription of drugs ..." | ||
| Vol 9, No 2 (2013) | ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES | Abstract similar documents |
| Z. M. Safiullina, S. V. Shalaev | ||
| "... дабигатрана, прямых ингибиторов Xа фактора свёртывания ривароксабана и апиксабана в лечении неклапанной формы ..." | ||
| Vol 14, No 1 (2018) | UTILIZING ENOXAPARIN IN THE MANAGEMENT OF ACUTE CORONARY SYNDROME | Abstract similar documents |
| O. V. Krikunova, R. I. Stryuk | ||
| "... Anticoagulant therapy is widely used in all forms of acute coronary syndrome (ACS) to inhibit ..." | ||
| Vol 18, No 6 (2022) | What is changing in the treatment of acute coronary syndrome in the Russian Federation? | Abstract similar documents |
| S. A. Boytsov, B. G. Alekyan, R. M. Shakhnovich, V. I. Ganyukov | ||
| "... with acute coronary syndrome (ACS) in the country, although a number of targets have not yet been reached ..." | ||
| Vol 13, No 2 (2017) | TREATMENT CHARACTERISTICS OF ACUTE CORONARY SYNDROME IN ELDERLY PATIENTS: PRACTICE OF N.I. PIROGOV CITY CLINICAL HOSPITAL №1 | Abstract similar documents |
| M. Yu. Gilyarov, M. O. Zheltoukhova, E. V. Konstantinova, M. D. Muksinova, L. S. Muradova, A. P. Nesterov, A. E. Udovichenko | ||
| "... syndrome (ACS) with existing guidelines and evaluation of ACS features during the last two years of working ..." | ||
| Vol 15, No 1 (2019) | Comparison between Bolus Intracoronary versus Bolus Intravenous Injection Regimens of Eptifibatide during Primary Percutaneous Coronary Intervention in Patients with Anterior ST-Segment Elevation Myocardial Infarction | Abstract PDF (Eng) similar documents |
| Mohamed Hassan Nab, Shaimaa Mostafa, Khaled Elrabat, Hamza Kabil, Neama Elmelegy | ||
| "... continuous I/V infusion. Features related to of myocardial salvage in the form of TIMI flow grade 3 ..." | ||
| Vol 6, No 3 (2010) | TREATMENT OF THE ACUTE CORONARY SYNDROME WITH ST SEGMENT ELEVATION AT THE PRE-HOSPITAL CARE | Abstract similar documents |
| S. N. Tereshchenko, I. V. Zhirov | ||
| "... Details of pre-hospital medical care organization in patients with acute coronary syndrome (ACS ..." | ||
| Vol 6, No 6 (2010) | TENEKTEPLASE: NEW POSSIBILITIES FOR SYSTEMIC THROMBOLYTIC THERAPY OF ACUTE CORONARY SYNDROME WITH ST-SEGMENT ELEVATION | Abstract similar documents |
| N. A. Novikova, A. E. Udovichenko | ||
| "... ) in patients with acute coronary syndrome (ACS) with ST segment elevation are discussed. The main factor ..." | ||
| Vol 3, No 1 (2007) | SECONDARY MITOCHONDRIAL DYSFUNCTION IN ACUTE CORONARY SYNDROME | Abstract similar documents |
| Y. A. Vasyuk, K. G. Kulikov, O. N. Kudryakov, O. V. Krikunova, I. A. Sadulaeva | ||
| "... diseases. The pathogenic peculiarities of acute coronary syndrome (ACS) which result in developing ..." | ||
| Vol 16, No 6 (2020) | Modern Antiplatelet Therapy for Percutaneous Coronary Intervention. How to Make the Right Choice? | Abstract similar documents |
| T. M. Uskach, A. S. Tereshchenko | ||
| "... Dual antiplatelet therapy is the most important step in acute coronary syndrome (ACS) treatment ..." | ||
| Vol 18, No 4 (2022) | Impact of the COVID-19 Pandemic on Myocardial Revascularization in Patients with Acute Coronary Syndrome in the Russian Federation | Abstract PDF (Eng) similar documents |
| B. G. Alekyan, S. A. Boytsov, V. I. Ganyukov, E. M. Manoshkina | ||
| "... (RF) with acute coronary syndrome (ACS) before the onset (2018-2019) and during the novel coronavirus ..." | ||
| Vol 19, No 1 (2023) | Acute Coronary Syndrome during the Pandemic New Coronavirus Infection | Abstract similar documents |
| O. M. Drapkina, A. Ya. Kravchenko, A. V. Budnevskiy, A. V. Kontsevaya, E. S. Ovsyannikov, E. S. Drobysheva | ||
| "... between COVID-19 and acute coronary syndrome (ACS), taking into account which will help to optimize ..." | ||
| Vol 8, No 3 (2012) | THE EFFICACY OF COMBINED BIOMARKER TESTS IN EARLY DIAGNOSTICS OF ACUTE MYOCARDIAL INFARCTION AFTER CLINICAL SYMPTOMS ONSET: ROLE OF HEART-TYPE FATTY ACID-BINDING PROTEIN | Abstract similar documents |
| O. V. Baturina, S. R. Gilyarevsky, I. M. Kuzmina, M. A. Godkov, E. V. Klychnikova | ||
| "... coronary syndrome (ACS) during first 6 hours after ACS symptoms onset were enrolled into the study ..." | ||
| Vol 18, No 6 (2022) | Acute Coronary Syndrome after Percutaneous Coronary Intervention: State of the Problem and Clinical Practice Data | Abstract similar documents |
| I. S. Egorova, N. N. Vezikova | ||
| "... of the development of acute coronary syndrome (ACS) in patients who had previously undergone percutaneous coronary ..." | ||
| Vol 12, No 5 (2016) | Features of the Hemostasis and Platelets Enzyme Activity in Patients with Different Sensitivity to Acetylsalicylic Acid by the Acute Coronary Syndrome | Abstract similar documents |
| I. Yu. Grinshtein, A. A. Savchenko, Yu. I. Grinshtein, M. M. Petrova | ||
| "... in acetylsalicylic acid (ASA) sensitive and resistant patients with acute coronary syndrome (ACS). Material ..." | ||
| Vol 7, No 2 (2011) | SOCIO-ECONOMIC DAMAGE BY ACUTE CORONARY SYNDROME IN RUSSIAN FEDERATION | Abstract similar documents |
| A. V. Kontsevaya, A. M. Kalinina, I. E. Koltunov, R. G. Oganov | ||
| "... Aim. To estimate the economic damage by acute coronary syndrome (ACS) in Russia in 2006-2009 ..." | ||
| 1 - 100 of 172 Items | 1 2 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
